CN Patent

CN102711813A — 抗凝血剂抗体

Assigned to Boehringer Ingelheim International GmbH · Expires 2012-10-03 · 14y expired

What this patent protects

本发明涉及对抗抗凝血剂、特别是对抗达比加群的抗体分子，以及所述抗体分子作为此类抗凝血剂的解毒剂的用途。

USPTO Abstract

本发明涉及对抗抗凝血剂、特别是对抗达比加群的抗体分子，以及所述抗体分子作为此类抗凝血剂的解毒剂的用途。

Drugs covered by this patent

dabigatran-etexilate-mesylate (DABIGATRAN ETEXILATE MESYLATE)

Patent Metadata

Patent number: CN102711813A
Jurisdiction: CN
Classification: —
Expires: 2012-10-03
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.